Key result
Apixaban was noninferior to warfarin for the resolution of post-MI left ventricular thrombus at 3 months.
Why the study?
Direct oral anticoagulants are frequently used to treat post-myocardial infarction left ventricular thrombus, but the efficacy and safety of apixaban compared to standard warfarin therapy required evaluation.
Does apixaban improve left ventricular thrombus resolution in patients with post-myocardial infarction left ventricular thrombus compared to warfarin?
RCT (n=50)
Open-label
randomized
Yes
Does apixaban improve left ventricular thrombus resolution in patients with post-myocardial infarction left ventricular thrombus compared to warfarin?
Apixaban is non-inferior to warfarin for the resolution of post-myocardial infarction left ventricular thrombus at 3 months.
Answers are grounded in this paper and cite their sources.
Apixaban noninferior to warfarin for post-MI LVT resolution; extends anticoagulation options with RCT confirmation.
Background Direct oral anticoagulants are frequently used to treat post-myocardial infarction (MI) left ventricular thrombus (LVT). This study was conducted to evaluate the efficacy and safety of use of apixaban, compared to the standard warfarin therapy, in post-MI LVT. Methods This open-label, randomized controlled trial included patients with post-acute or recent anterior wall MI with transthoracic echocardiography-confirmed LVT. Patients were randomized to receive either apixaban 5 mg twice daily or warfarin to achieve an international normalized ratio of 2-3, in addition to dual antiplatelet therapy. The primary endpoint was LVT resolution at 3 months, with a noninferiority margin of 95% for apixaban compared to warfarin. The secondary endpoint was major adverse cardiovascular events (MACE) or any relevant bleeding according to the Bleeding Academic Research Consortium (BARC) classification. Results Fifty patients were enrolled from 3 centres. The use of dual or single antiplatelet agents was similar in the 2 groups. The number of 1-, 3-, and 6-month LVT resolutions were 10 (40.0%), 19 (76.0%), and 23 (92.0%) in the apixaban group, and 14 (56%), 20 (80.0%), and 24 (96.0%) in the warfarin group, respectively, without significant differences ( P < 0.036 for noninferiority at 3 months). Patients taking warfarin required longer hospital stays and more outpatient visits. Multivariate adjustment analysis revealed left ventricular aneurysm, larger baseline LVT area and lower left ventricular ejection fraction to be independent predictors of LVT persistence at 3 months. No MACE occurred in either group; 1 BARC-2 bleeding event occurred with warfarin. Conclusions Apixaban was not inferior to warfarin in the resolution of post-MI LVT.
No takes yet. Share an insight, caveat, or question.
Youssef et al. (2022) conducted an RCT in Post-myocardial infarction left ventricular thrombus (n=50). Apixaban vs. Warfarin was evaluated on LVT resolution at 3 months (p=< 0.036 for noninferiority). Apixaban was noninferior to warfarin for the resolution of post-MI left ventricular thrombus at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: